The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Current Concepts in Antifungal Pharmacology
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Cornely, O. A., Maertens, J., Winston, D. J., Perfect, J., Ullmann, A. J., Walsh, T. J., Helfgott, D., Holowiecki, J., Stockelberg, D., Goh, Y.-T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061094 · Cited by 1,813
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
Ullmann, A. J., Lipton, J. H., Vesole, D. H., Chandrasekar, P., Langston, A., Tarantolo, S. R., Greinix, H., Morais de Azevedo, W., Reddy, V., Boparai, N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061098 · Cited by 1,345
Antifungal agents: mechanisms of action
Odds, F. C., Brown, A. J. P., & Gow, N. A. R. (2003) · Trends in Microbiology · doi:10.1016/s0966-842x(03)00117-3 · Cited by 1,202
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
Desta, Z., Zhao, X., Shin, J.-G., & Flockhart, D. A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00002 · Cited by 942
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930
Anidulafungin versus Fluconazole for Invasive Candidiasis
Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066906 · Cited by 894
Pascual, A., Calandra, T., Bolay, S., Buclin, T., Bille, J., & Marchetti, O. (2008) · Clinical Infectious Diseases · doi:10.1086/524669 · Cited by 887
Walsh, T. J., Raad, I., Patterson, T. F., Chandrasekar, P., Donowitz, G. R., Graybill, R., Greene, R. E., Hachem, R., Hadley, S., Herbrecht, R., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/508774 · Cited by 752
Cornely, O. A., Maertens, J., Bresnik, M., Ebrahimi, R., Ullmann, A. J., Bouza, E., Heussel, C. P., Lortholary, O., Rieger, C., Boehme, A., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/514341 · Cited by 751
Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections
Perfect, J. R., Marr, K. A., Walsh, T. J., Greenberg, R. N., DuPont, B., de la Torre‐Cisneros, J., Just‐Nubling, G., Schlamm, H. T., Lutsar, I., Espinel‐Ingroff, A., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374557 · Cited by 680
Maertens, J., Raad, I., Petrikkos, G., Boogaerts, M., Selleslag, D., Petersen, F. B., Sable, C. A., Kartsonis, N. A., Ngai, A., Taylor, A., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/423381 · Cited by 658
Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis
Pappas, P. G., Rotstein, C. M. F., Betts, R. F., Nucci, M., Talwar, D., De Waele, J. J., Vazquez, J. A., Dupont, B. F., Horn, D. L., Ostrosky-Zeichner, L., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/520980 · Cited by 638
Antifungal drug resistance of pathogenic fungi
Kontoyiannis, D. P., & Lewis, R. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08162-x · Cited by 553
Self-citationResistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512
Amphotericin B: current understanding of mechanisms of action
Brajtburg, J., Powderly, W. G., Kobayashi, G. S., & Medoff, G. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.2.183 · Cited by 504
Antifungal therapeutic drug monitoring: established and emerging indications
Andes, D., Pascual, A., & Marchetti, O. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00705-08 · Cited by 490
Wingard, J. R., Carter, S. L., Walsh, T. J., Kurtzberg, J., Small, T. N., Baden, L. R., Gersten, I. D., Mendizabal, A. M., Leather, H. L., Confer, D. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268151 · Cited by 482
Pharmacokinetic/Pharmacodynamic Profile of Voriconazole
Theuretzbacher, U., Ihle, F., & Derendorf, H. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645070-00002 · Cited by 475
Brüggemann, R. J. M., Alffenaar, J. C., Blijlevens, N. M. A., Billaud, E. M., Kosterink, J. G. W., Verweij, P. E., & Burger, D. M. (2009) · Clinical Infectious Diseases · doi:10.1086/598327 · Cited by 457
Pharmacokinetic/Pharmacodynamic Profile of Posaconazole
Li, Y., Theuretzbacher, U., Clancy, C. J., Nguyen, M. H., & Derendorf, H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11319340-000000000-00000 · Cited by 450
Marr, K. A., Crippa, F., Leisenring, W., Hoyle, M., Boeckh, M., Balajee, S. A., Nichols, W. G., Musher, B., & Corey, L. (2004) · Blood · doi:10.1182/blood-2003-08-2644 · Cited by 442
Voriconazole therapeutic drug monitoring
Smith, J., Safdar, N., Knasinski, V., Simmons, W., Bhavnani, S. M., Ambrose, P. G., & Andes, D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1570-1572.2006 · Cited by 399
Improved outcome in central nervous system aspergillosis, using voriconazole treatment
Schwartz, S. (2005) · Blood · doi:10.1182/blood-2005-02-0733 · Cited by 391
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Treatment of invasive aspergillosis with itraconazole
Denning, D. W., Tucker, R. M., Hansen, L. H., & Stevens, D. A. (1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90475-0 · Cited by 364
Krishna, G., Moton, A., Ma, L., Medlock, M. M., & McLeod, J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01034-08 · Cited by 349
Douglas, C. M., D'Ippolito, J. A., Shei, G. J., Meinz, M., Onishi, J., Marrinan, J. A., Li, W., Abruzzo, G. K., Flattery, A., Bartizal, K., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2471 · Cited by 344
Pfaller, M. A., Diekema, D. J., Andes, D., Arendrup, M. C., Brown, S. D., Lockhart, S. R., Motyl, M., & Perlin, D. S. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.004 · Cited by 334
Courtney, R., Wexler, D., Radwanski, E., Lim, J., & Laughlin, M. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01977.x · Cited by 327
Pfaller, M. A., Andes, D., Diekema, D. J., Espinel-Ingroff, A., & Sheehan, D. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.09.002 · Cited by 314
Pharmacology of Systemic Antifungal Agents
Ashley, E. S. D., Lewis, R., Lewis, J. S., Martin, C., & Andes, D. (2006) · Clinical Infectious Diseases · doi:10.1086/504492 · Cited by 313
Self-citationSaad, A. H., DePestel, D. D., & Carver, P. L. (2006) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.12.1730 · Cited by 295
Systemic Antifungal Agents: Drug Interactions of Clinical Significance
Albengres Herv??, E., Lou??, L., & Tillement, J.-P. (1998) · Drug Safety · doi:10.2165/00002018-199818020-00001 · Cited by 280
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Nagy, E., Dobiasova, S., Rinaldi, M., Barton, R., Veselov, A., & the Global Antifungal Surveillance Group (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01915-07 · Cited by 259
Tan, K., Brayshaw, N., Tomaszewski, K., Troke, P., & Wood, N. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005283837 · Cited by 256
Jang, S. H., Colangelo, P. M., & Gobburu, J. V. S. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.64 · Cited by 239
Francis, P., & Walsh, T. J. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.6.1003 · Cited by 232
In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species
Andes, D., Diekema, D. J., Pfaller, M. A., Bohrmuller, J., Marchillo, K., & Lepak, A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01584-09 · Cited by 226
Itraconazole Therapy for Cryptococcal Meningitis and Cryptococcosis
Denning, D. W. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.149.10.2301 · Cited by 215
Voriconazole Pharmacokinetics and Pharmacodynamics in Children
Neely, M., Rushing, T., Kovacs, A., Jelliffe, R., & Hoffman, J. (2010) · Clinical Infectious Diseases · doi:10.1086/648679 · Cited by 214
Mellado, E., Garcia-Effron, G., Alcazar-Fuoli, L., Cuenca-Estrella, M., & Rodriguez-Tudela, J. L. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.7.2747-2750.2004 · Cited by 210
Ezzet, F., Wexler, D., Courtney, R., Krishna, G., Lim, J., & Laughlin, M. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544020-00006 · Cited by 208
Wiederhold, N. P., Kontoyiannis, D. P., Chi, J., Prince, R. A., Tam, V. H., & Lewis, R. E. (2004) · The Journal of Infectious Diseases · doi:10.1086/424465 · Cited by 207
Self-citationCongestive heart failure associated with itraconazole
Ahmad, S. R., Singer, S. J., & Leissa, B. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04891-1 · Cited by 200
Trifilio, S., Pennick, G., Pi, J., Zook, J., Golf, M., Kaniecki, K., Singhal, S., Williams, S., Winter, J., Tallman, M., et al. (2007) · Cancer · doi:10.1002/cncr.22568 · Cited by 199
Andes, D., & van Ogtrop, M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.9.2116 · Cited by 192
Mann, P. A., Parmegiani, R. M., Wei, S.-Q., Mendrick, C. A., Li, X., Loebenberg, D., DiDomenico, B., Hare, R. S., Walker, S. S., & McNicholas, P. M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.2.577-581.2003 · Cited by 189
Tucker, R. M., Denning, D. W., Hanson, L. H., Rinaldi, M. G., Graybill, J. R., Sharkey, P. K., Pappagianis, D., & Stevens, D. A. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.1.165 · Cited by 183
Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients
Trifilio, S., Ortiz, R., Pennick, G., Verma, A., Pi, J., Stosor, V, Zembower, T., & Mehta, J. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704828 · Cited by 180
Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
Andes, D., Stamsted, T., & Conklin, R. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.922-926.2001 · Cited by 180
Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis
Andes, D., Marchillo, K., Conklin, R., Krishna, G., Ezzet, F., Cacciapuoti, A., & Loebenberg, D. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.137-142.2004 · Cited by 177
Louie, A., Deziel, M., Liu, W., Drusano, M. F., Gumbo, T., & Drusano, G. L. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.5058-5068.2005 · Cited by 164
Association of fluconazole pharmacodynamics with mortality in patients with candidemia
Baddley, J. W., Patel, M., Bhavnani, S. M., Moser, S. A., & Andes, D. R. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00116-08 · Cited by 162
Kauffman, C. A. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2009.02.002 · Cited by 160
Pai, M. P., Turpin, R. S., & Garey, K. W. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00474-06 · Cited by 159
Science, medicine, and the future: Stem cell transplantation
Lennard, A. L. (2000) · BMJ · doi:10.1136/bmj.321.7258.433 · Cited by 159
Making sense of itraconazole pharmacokinetics
Prentice, A. G., & Glasmacher, A. G. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki220 · Cited by 144
Management of Drug and Food Interactions with Azole Antifungal Agents in Transplant Recipients
Dodds‐Ashley, E. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.8.842 · Cited by 143
Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children
Walsh, T. J., Driscoll, T., Milligan, P. A., Wood, N., Schlamm, H. T., Groll, A. H., Jafri, H. S., Arrieta, A. C., Klein, N. J., & Lutsar, I. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00896-10 · Cited by 143
Therapeutic drug monitoring for triazoles
Hope, W. W., Billaud, E. M., Lestner, J. M., & Denning, D. W. (2008) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283184611 · Cited by 142
Mode of action of 5-fluorocytosine
Diasio, R. B., Bennett, J. E., & Myers, C. E. (1978) · Biochemical Pharmacology · doi:10.1016/0006-2952(78)90507-5 · Cited by 141
Update on antifungal drug resistance mechanisms of Aspergillus fumigatus
Chamilos, G., & Kontoyiannis, D. P. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2006.01.001 · Cited by 138
Potential Basis for Amphotericin B Resistance in Aspergillus terreus
Blum, G., Perkhofer, S., Haas, H., Schrettl, M., Würzner, R., Dierich, M. P., & Lass‐Flörl, C. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01280-07 · Cited by 138
Pfaller, M. A., Messer, S. A., Hollis, R. J., Boyken, L. B., Tendolkar, S., Kroeger, J. S., & Diekema, D. J. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00946-09 · Cited by 131
Pappas, P. G., Rotstein, C. M. F., Rf, B., Nucci, M., Talwar, D., Waele, J. J. D., Jm, D. L. V. V., Dupont, B., Horn, D., Ostrosky‐Zeichner, L., et al. (2008) · Ghent University Academic Bibliography (Ghent University) · Cited by 130
Itraconazole in Cyclodextrin Solution
Stevens, D. A. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.8.603.31529 · Cited by 129
Toxicodynamics of Itraconazole: Implications for Therapeutic Drug Monitoring
Lestner, J. M., Roberts, S. A., Moore, C. B., Howard, S. J., Denning, D. W., & Hope, W. W. (2009) · Clinical Infectious Diseases · doi:10.1086/605499 · Cited by 129
Cartledge, J. D., Midgely, J., & Gazzard, B. (1997) · Journal of Clinical Pathology · doi:10.1136/jcp.50.6.477 · Cited by 124
The Discovery and Development of Amphotericin B
Dutcher, J. D. (1968) · Diseases of the Chest · doi:10.1378/chest.54.supplement_1.296 · Cited by 122
Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration
Purkins, L., Wood, N., Ghahramani, P., Love, E. R., Eve, M. D., & Fielding, A. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01997.x · Cited by 120
Andes, D., Safdar, N., Marchillo, K., & Conklin, R. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.674-684.2006 · Cited by 116
Pharmacokinetics and Pharmacodynamics of Antifungals
Andes, D. R. (2006) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2006.06.007 · Cited by 115
Echinocandins for Candidemia in Adults without Neutropenia
Bennett, J. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmct060052 · Cited by 111
Howard, S. J., Lestner, J. M., Sharp, J., Gregson, L., Goodwin, J., Slater, J., Majithiya, J. B., Warn, P. A., & Hope, W. W. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir023 · Cited by 108
New generation azole antifungals in clinical investigation
Girmenia, C. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903176407 · Cited by 107
Wiederhold, N. P., Tam, V. H., Chi, J., Prince, R. A., Kontoyiannis, D. P., & Lewis, R. E. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.469-473.2006 · Cited by 104
Self-citationHong, Y., Shaw, P. J., Nath, C. E., Yadav, S. P., Stephen, K. R., Earl, J. W., & McLachlan, A. J. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.935-942.2006 · Cited by 102
Fungal Infections of the CNS: Treatment Strategies for the Immunocompromised Patient
Black, K. E., & Baden, L. R. (2007) · CNS Drugs · doi:10.2165/00023210-200721040-00004 · Cited by 101
Glasmacher, A. G., Hahn, C., Molitor, E., Marklein, G., Sauerbruch, T., & Schmidt‐Wolf, I. G. H. (1999) · Mycoses · doi:10.1046/j.1439-0507.1999.00518.x · Cited by 99
Andes, D. R., & van Ogtrop, M. L. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.938-942.2000 · Cited by 96
Renal impairment and Amphotericin B formulations in patients with invasive fungal infections
Saliba, F., & Dupont, B. (2008) · Medical Mycology · doi:10.1080/13693780701730469 · Cited by 94
Krishna, G., Parsons, A. C., Kantesaria, B. S., et al. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167507 · Cited by 85
Drug Interactions in Infectious Diseases
Piscitelli, S. C., & Rodvold, K. A. (2000) · Humana Press eBooks · doi:10.1007/978-1-59259-025-4 · Cited by 82
Kohl, V., Müller, C., Cornely, O. A., Abduljalil, K., Fuhr, U., Vehreschild, J. J., Scheid, C., Hallek, M. J., & Rüping, M. J. G. T. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01027-09 · Cited by 79
Activity of terbinafine against serious fungal pathogens
Ryder, N. S. (1999) · Mycoses · doi:10.1111/j.1439-0507.1999.tb00026.x · Cited by 79
The pharmacokinetics of oral itraconazole in AIDS patients
Smith, D., de Velde, V. V., Woestenborghs, R. J. H., & Gazzard, B. (1992) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1992.tb05478.x · Cited by 77
Flucytosine therapeutic monitoring: 15 years experience from the UK
Pasqualotto, A. C., Howard, S. J., Moore, C. B., & Denning, D. W. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl550 · Cited by 72
Amphotericin B Activation of Human Genes Encoding for Cytokines
Rogers, P. D., Jenkins, J. K., Chapman, S. W., et al. (1998) · The Journal of Infectious Diseases · doi:10.1086/314495 · Cited by 71
Efficacy of Posaconazole in a Murine Model of Central Nervous System Aspergillosis
Imai, J. K., Singh, G., Clemons, K. V., & Stevens, D. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.4063-4066.2004 · Cited by 59
Omeprazole Significantly Reduces Posaconazole Serum Trough Level
Alffenaar, J. C., van Assen, S., van der Werf, T. S., Kosterink, J. G. W., & Uges, D. R. A. (2009) · Clinical Infectious Diseases · doi:10.1086/597110 · Cited by 58
Posaconazole: An Oral Triazole with an Extended Spectrum of Activity
Rachwalski, E. J., Wieczorkiewicz, J. T., & Scheetz, M. H. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1l005 · Cited by 53
Fungal CNS infections in patients with hematologic malignancy
Pagano, L., Caira, M., Falcucci, P., & Fianchi, L. (2005) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.3.5.775 · Cited by 48
Abutarif, M. A., Krishna, G., & Statkevich, P. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903485056 · Cited by 40
Pappas et al. (2007; 45:883–93)
(2008) · Clinical Infectious Diseases · doi:10.1086/590000 · Cited by 31
Clinical pharmacodynamics of antifungals
Andes, D. R. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00063-1 · Cited by 29
Kauffman, C. A., Malani, A. N., Easley, C., & Kirkpatrick, P. J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2270 · Cited by 29
Variability in Polyene Content and Cellular Toxicity Among Deoxycholate Amphotericin B Formulations
Cleary, J. D., Rogers, P. D., & Chapman, S. W. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.5.572.32209 · Cited by 28
Voriconazole-Associated Phototoxicity
Riahi, R. R., & Cohen, P. R. (2011) · Dermatology Online Journal · doi:10.5070/d352h3f976 · Cited by 27
Managing drug interactions in the patient with aspergillosis
Lewis, R. E. (2006) · Medical Mycology · doi:10.1080/13693780600835724 · Cited by 21
Self-citation
Cited by
The antifungal arsenal: alternative drugs and future targets
Wiederhold, N. P. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.09.002 · Cited by 149
Lionakis, M. S., Lewis, R. E., & Kontoyiannis, D. P. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy473 · Cited by 145
Self-citationHepatocellular Toxicity of Imidazole and Triazole Antimycotic Agents
Haegler, P., Joerin, L., Krähenbühl, S., & Bouitbir, J. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx029 · Cited by 79
Ning, Y., Xiao, M., Perlin, D. S., Zhao, Y., Lu, M., Li, Y., Luo, Z., Dai, R., Li, S., Xu, J., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2153086 · Cited by 63
Optimizing antifungal choice and administration
Andes, D. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.761135 · Cited by 63
Metadata
- Authors
- Lewis, R. E.
- Venue
- Mayo Clinic Proceedings
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 86
- Issue
- 8
- Pages
- 805-817
- ISSN
- 0025-6196 (ISSN-L)
- OpenAlex
- W2085986706
- Cited by
- 377
- References
- 106
- FWCI
- 7.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.